SUNDAY, March 10 (HealthDay News) -- A newer class of diabetes drugs may offer an extra benefit: A new study suggests these medications lower the odds of suffering heart failure.
Researchers from Henry Ford Hospital in Detroit found that patients taking so-called GLP-1 drugs -- including brand-name medications such as Byetta, Januvia and Victoza -- were more than 40 percent less likely to be hospitalized for heart failure than patients prescribed other blood sugar-lowering medications. GLP-1 diabetes drugs have been in use for only the last several years and are considered second-line treatments after well-established medications such as metformin, physicians said.
"I don't think we can say this will magically prevent all heart failure deaths, but the strength of the association warrants more investigation," said study author and cardiologist Dr. David Lanfear. "Heart failure is a very common disease . . . but something about diabetics make them definitely at increased risk for developing heart failure."
The study is to be presented Sunday at the American College of Cardiology's annual meeting in San Francisco. Evidence presented at medical meetings has not been peer-reviewed and is considered preliminary.
According to the U.S. National Institutes of Health, about 6 million Americans suffer from heart failure, which occurs when the heart can't efficiently pump blood through the body. Diabetics, who now number 25 million in the United States, are between two and four times more likely than those without the condition to die of heart disease, which includes heart attacks, heart failure and other cardiac problems.
In the retrospective study, Lanfear and his colleagues examined data from more than 4,400 patients taking diabetes medications between 2000 and 2012. About 1,500 were taking GLP-1 medications and nearly 3,000 were not.
Over an average nine-month fol
All rights reserved